Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Sanofi and SK Bioscience Expand Collaboration for Next-Generation PCV Development
Dec 23, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyHealth Care
Description
Sanofi SA and SK Bioscience Co. Ltd have entered into an expanded partnership to co-fund research and development costs for next-generation PCVs, with Sanofi paying €50m upfront to SK Bioscience. Once registered, Sanofi will commercialize the vaccines worldwide except for South Korea, where SK Bioscience will have commercial exclusivity. SK Bioscience will also receive royalty payments on product sales outside South Korea.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months